Cytokinetics secures up to $575M in royalty deal

Cytokinetics secures up to $575M in royalty deal, frustrating investors

The agreement will give Cytokinetics $250 million at closing and as much as $575 million in total. Royalty Pharma, a specialist in these types ...

Cytokinetics Reports Third Quarter 2024 Financial Results

With more than $1 billion on the balance sheet and access to additional long-term capital, we are well-funded and well-prepared to sustain ...

Cytokinetics Reports Third Quarter 2024 Financial Results

With more than $1 billion on the balance sheet and access to additional long-term capital, we are well-funded and well-prepared to sustain ...

Ben Fidler on LinkedIn: Cytokinetics secures up to $575M in royalty ...

Cytokinetics secures up to $575M in royalty deal, frustrating investors.

Cytokinetics Reports Second Quarter 2024 Financial Results

In May, we secured contingent access to more than $1 billion in funding to support the potential global launch of aficamten as well as to ...

Ben Fidler on X: "Cytokinetics secures up to $575M in royalty deal ...

Cytokinetics secures up to $575M in royalty deal, frustrating investors https://t.co/fMnuawVT7f by @NedPagliarulo $CYTK - 15% $NVS $BMY.

Royalty Pharma and Cytokinetics Announce Expanded Strategic ...

Royalty Pharma invests up to $575M in Cytokinetics to boost aficamten commercialization and cardiovascular R&D. Immediate $250M funding secured. Read more.

Cytokinetics Reports Second Quarter 2024 Financial Results

In May, we secured contingent access to more than $1 billion in funding to support the potential global launch of aficamten as well as to ...

Cytokinetics Reports Second Quarter 2024 Financial Results

On May 22, 2024, the company entered into a strategic funding collaboration with Royalty Pharma totaling up to $575 ... purchase agreement with ...

News feed - Estonia Innovation Ecosystem

Royalty Pharma and Cytokinetics have expanded their strategic funding collaboration, totaling up to $575 million, to support the commercial launch of aficamten ...

Cytokinetics company information, funding & investors - Dealroom

Cytokinetics Announces Pricing of Public Offering of Common Stock | $CYTK Stock News · Cytokinetics Secures $575M Funding from Royalty Pharma.

News feed | Basque startup ecosystem

Cytokinetics. South San Francisco, United States. Cytokinetics Secures $575M Funding from Royalty Pharma ... up to $575 million, to support the commercial launch ...

2024-Corporate-Presentation-082424.pdf - Cytokinetics

agreements with Royalty Pharma, or Royalty Pharma's decision to opt ... $175M** already secured with Royalty Pharma (RP); total available.

SFJ Pharmaceuticals, Inc - Company Details :: In Vivo

Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ...

Lisa Smith - biopharma royalty deals on the rise - LinkedIn

Cytokinetics' recent $575M deal with Royalty ... The deal restructures royalty terms for aficamten, with royalties set at 4.5% up ... secured the support of ...

SEC Filing | Cytokinetics, Inc.

In May, we secured contingent access to more than $1 billion in funding to support the potential global launch of aficamten as well as to ...

Cytokinetics secures $575M in royalty deal - Business Fortune

Cytokinetics plans to seek FDA approval for Aficamten in the third quarter. Royalty funds will support preparation, and sales royalties are set at 4.5% up to $5 ...

Cytokinetics Inc (KK3A.BE) latest stock news and headlines – Yahoo ...

CYTK · NVS · Cytokinetics secures up to $575M in royalty deal, frustrating investors. The ...

Biotech News - BioPharma Dive

Cytokinetics secures up to $575M in royalty deal, frustrating investors. The biotech's decision to give Royalty Pharma a greater share of future drug sales ...

Forward-Looking Statements - Cytokinetics

Equity Financing Royalty Pharma Deal. ~ $500 M. $250 M. $325 M in optional ... Four separate components providing $250M upon closing; up to $575M total.